Akero Therapeutics, Inc. (NASDAQ:AKRO) Receives $41.13 Average PT from Analysts

Akero Therapeutics, Inc. (NASDAQ:AKRO) has been assigned an average recommendation of “Moderate Buy” from the nine analysts that are currently covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a hold recommendation and eight have given a buy recommendation to the company. The average 1 year target price among brokers that have updated their coverage on the stock in the last year is $41.13.

Several equities research analysts have recently commented on AKRO shares. Cantor Fitzgerald reissued an “overweight” rating on shares of Akero Therapeutics in a research note on Thursday, June 20th. HC Wainwright reissued a “buy” rating and issued a $50.00 target price on shares of Akero Therapeutics in a research note on Tuesday. Finally, Wolfe Research started coverage on Akero Therapeutics in a research note on Tuesday, June 11th. They issued an “outperform” rating for the company.

Akero Therapeutics Trading Up 3.9 %

Shares of AKRO opened at $28.00 on Tuesday. The stock has a fifty day moving average price of $26.28 and a two-hundred day moving average price of $23.98. The company has a debt-to-equity ratio of 0.04, a quick ratio of 24.89 and a current ratio of 24.89. Akero Therapeutics has a 52-week low of $11.25 and a 52-week high of $51.81. The company has a market cap of $1.94 billion, a price-to-earnings ratio of -8.75 and a beta of -0.26.

Akero Therapeutics (NASDAQ:AKRO) last issued its quarterly earnings data on Friday, August 9th. The company reported ($0.81) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.90) by $0.09. Analysts predict that Akero Therapeutics will post -3.64 EPS for the current fiscal year.

Insider Activity

In related news, CEO Andrew Cheng sold 1,738 shares of the company’s stock in a transaction dated Tuesday, September 10th. The stock was sold at an average price of $26.18, for a total transaction of $45,500.84. Following the sale, the chief executive officer now owns 605,417 shares in the company, valued at $15,849,817.06. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other Akero Therapeutics news, CEO Andrew Cheng sold 1,738 shares of the business’s stock in a transaction that occurred on Tuesday, September 10th. The stock was sold at an average price of $26.18, for a total transaction of $45,500.84. Following the transaction, the chief executive officer now owns 605,417 shares of the company’s stock, valued at $15,849,817.06. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, insider Catriona Yale sold 3,871 shares of the business’s stock in a transaction that occurred on Wednesday, September 18th. The stock was sold at an average price of $27.56, for a total value of $106,684.76. Following the transaction, the insider now directly owns 75,294 shares in the company, valued at approximately $2,075,102.64. The disclosure for this sale can be found here. Insiders have sold a total of 283,042 shares of company stock worth $7,679,955 over the last three months. Corporate insiders own 7.94% of the company’s stock.

Institutional Trading of Akero Therapeutics

Several large investors have recently modified their holdings of the stock. Janus Henderson Group PLC grew its holdings in shares of Akero Therapeutics by 42.2% during the 1st quarter. Janus Henderson Group PLC now owns 6,121,970 shares of the company’s stock worth $154,589,000 after purchasing an additional 1,815,569 shares in the last quarter. Price T Rowe Associates Inc. MD grew its holdings in shares of Akero Therapeutics by 10.5% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 4,060,479 shares of the company’s stock worth $102,569,000 after purchasing an additional 384,555 shares in the last quarter. Vanguard Group Inc. grew its holdings in shares of Akero Therapeutics by 19.0% during the 1st quarter. Vanguard Group Inc. now owns 3,669,923 shares of the company’s stock worth $92,702,000 after purchasing an additional 584,875 shares in the last quarter. RTW Investments LP acquired a new stake in shares of Akero Therapeutics during the 4th quarter worth $83,891,000. Finally, Wellington Management Group LLP grew its holdings in shares of Akero Therapeutics by 247.7% during the 4th quarter. Wellington Management Group LLP now owns 2,881,989 shares of the company’s stock worth $67,294,000 after purchasing an additional 2,053,028 shares in the last quarter.

About Akero Therapeutics

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.